Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer. Whether a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback